Back to news

TXG rises as recent product rollout, partnerships and analyst target hikes keep momentum alive

Investivoq PriceTracker

10x Genomics (TXG) is up 5.8% today. Here is some analysis on what might have caused this price movement.

Analysis: The move appears tied to continued momentum from several recent positives rather than a single same-day announcement. This could be because investors are still reacting to the company’s Atera launch and shipment start, a new oncology-focused collaboration, higher analyst price targets in October, and an improved 2026 revenue outlook.

Details:

  • The company’s most recent investor update on October 13 set its third-quarter 2026 results release for November 5, which may be drawing attention ahead of earnings.
  • Late September brought the start of global Atera shipments, giving investors a fresh commercial milestone for one of the company’s newest spatial biology platforms.
  • On October 7, 10x Genomics announced a new collaboration aimed at single cell and spatial applications across solid tumors and blood cancers, adding to the growth narrative around clinical and translational research use cases.
  • In its August second-quarter release, the company raised full-year 2026 revenue guidance to $610 million to $630 million and highlighted strong early order flow for Atera.

    • Sources:

    10x Genomics, SEC, Benzinga

    Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

    $TXG Insider Trading Activity

    TXG Insider Trades

    $TXG insiders have traded $TXG stock on the open market 38 times in the past 6 months. Of those trades, 0 have been purchases and 38 have been sales.

    Here’s a breakdown of recent trading of $TXG stock by insiders over the last 6 months:

    • SERGE SAXONOV (Chief Executive Officer) has made 0 purchases and 15 sales selling 112,924 shares for an estimated $5,609,562.
    • ADAM TAICH (Chief Financial Officer) has made 0 purchases and 5 sales selling 78,652 shares for an estimated $4,446,341.
    • JOHN R STUELPNAGEL has made 0 purchases and 5 sales selling 40,000 shares for an estimated $2,390,127.
    • BENJAMIN J. HINDSON (See Remarks) has made 0 purchases and 2 sales selling 25,413 shares for an estimated $1,154,259.
    • SHEHNAAZ SULIMAN has made 0 purchases and 9 sales selling 13,653 shares for an estimated $791,901.
    • SARAH A. TEICHMANN has made 0 purchases and 2 sales selling 7,551 shares for an estimated $432,278.

    To track insider transactions, check out Investivoq's insider trading dashboard. You can access data on insider stock transactions through the Investivoq API insider transaction endpoint.

    Investivoq Alerts
    Receive TXG Data Alerts
    Get market-moving data, filings, and signals for TXG in real time.
    Sign Up

    $TXG Hedge Fund Activity

    We have seen 190 institutional investors add shares of $TXG stock to their portfolio, and 185 decrease their positions in their most recent quarter.

    Here are some of the largest recent moves:

    • PRICE T ROWE ASSOCIATES INC /MD/ added 4,375,792 shares (+2681.0%) to their portfolio in Q2 2026, for an estimated $167,767,865
    • MILLENNIUM MANAGEMENT LLC removed 1,951,581 shares (-94.4%) from their portfolio in Q2 2026, for an estimated $74,823,615
    • POINT72 ASSET MANAGEMENT, L.P. added 1,852,776 shares (+inf%) to their portfolio in Q2 2026, for an estimated $71,035,431
    • ARK INVESTMENT MANAGEMENT LLC removed 1,714,260 shares (-14.6%) from their portfolio in Q2 2026, for an estimated $65,724,728
    • CASDIN CAPITAL, LLC removed 1,225,000 shares (-53.8%) from their portfolio in Q2 2026, for an estimated $46,966,500
    • SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 1,087,150 shares (+inf%) to their portfolio in Q2 2026, for an estimated $41,681,331
    • BALYASNY ASSET MANAGEMENT L.P. removed 989,522 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $37,938,273

    To track hedge funds' stock portfolios, check out Investivoq's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Investivoq API 13F endpoint.

    $TXG Government Contracts

    We have seen $3,952,499 of award payments to $TXG over the last year.

    Here are some of the awards which we have have seen pay out the most over the last year:

    • PROSTHETIST, PROSTHETIST TECHNICIAN, AND PROSTHETIST ASSISTANT IN THE DEPARTMENT OF SURGICAL SERVICES AND R...: $371,793
    • GENE EXPRESSION REAGENTS: $226,900

    To track government contracts to publicy traded companies, check out Investivoq's government contracts dashboard. You can access data on government contracts through the Investivoq API government contracts endpoint.

    $TXG Price Targets

    Multiple analysts have issued price targets for $TXG recently. We have seen 6 analysts offer price targets for $TXG in the last 6 months, with a median target of $41.0.

    Here are some recent targets:

    • Tejas Savant from Morgan Stanley set a target price of $37.0 on 07/09/2026
    • Patrick Donnelly from Citigroup set a target price of $45.0 on 07/08/2026
    • Eric Winmill from Scotiabank set a target price of $100.0 on 07/08/2026
    • David Westenberg from Piper Sandler set a target price of $42.0 on 07/01/2026
    • Luke Sergott from Barclays set a target price of $40.0 on 06/24/2026
    • Casey Woodring from JP Morgan set a target price of $20.0 on 05/12/2026

    This article is not financial advice. See Investivoq's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.